Lori Montgomery
Research Subjects
Lori Montgomery has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ben Vandermeer
B. Vandermeer, Epicore Centre, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Christina Korownyk
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
1 shared publication Deborah Lynam
Primary Health Care Information Network, Edmonton, Alberta, Canada
1 shared publication- Frank P. MacMaster
Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Hance Clarke
Department of Anesthesia and Pain Management, University Health Network, Toronto, Canada
1 shared publication I Lala
Department of Clinical Pharmacology, University of Zimbabwe, P.O. Box A 178, Avondale, Harare, Zimbabwe
1 shared publication
Latest Publications
- 7 August 2020
- Published by Wiley in Journal of Neuroscience Research
- Vol. 100 (1) , 10-18
Pain management with opioids in adults
Given the ubiquitous nature of opioids in the treatment of pain, it is an interesting paradox that this class of medications also represents one of the least understood components of clinical pain medicine. For many years, there has been intense interest in the mechanisms of opioid activity, but this has not resulted in a corresponding increase in convincing clinical data. This review focuses primarily on the evidence surrounding the long‐term use of opioids in chronic pain, but discussions of this research are often conflated with the very different data governing acute and cancer‐related pain, where evidence of efficacy is clearer. It is therefore important to clarify the evidence‐based indications for opioid therapy. There remains very little evidence that opioids improve function or quality of life beyond 3 months in people with chronic pain conditions. In all three patient populations, the development of tolerance, dependence, hyperalgesia and withdrawal are key phenomena that affect the patient experience, and in particular the decision to remain on opioids in the long term. This is a common thread that connects the opioid literature in all of these spheres, and justifies the burgeoning interest in these phenomena in the basic science literature. There is an urgent need to address these negative consequences of opioid use, in order to maximize the therapeutic benefit that opioids can offer.
- 7 August 2020
- Published by Wiley in Journal of Neuroscience Research
- Vol. 100 (1) , 10-18
Pain management with opioids in adults
Given the ubiquitous nature of opioids in the treatment of pain, it is an interesting paradox that this class of medications also represents one of the least understood components of clinical pain medicine. For many years, there has been intense interest in the mechanisms of opioid activity, but this has not resulted in a corresponding increase in convincing clinical data. This review focuses primarily on the evidence surrounding the long‐term use of opioids in chronic pain, but discussions of this research are often conflated with the very different data governing acute and cancer‐related pain, where evidence of efficacy is clearer. It is therefore important to clarify the evidence‐based indications for opioid therapy. There remains very little evidence that opioids improve function or quality of life beyond 3 months in people with chronic pain conditions. In all three patient populations, the development of tolerance, dependence, hyperalgesia and withdrawal are key phenomena that affect the patient experience, and in particular the decision to remain on opioids in the long term. This is a common thread that connects the opioid literature in all of these spheres, and justifies the burgeoning interest in these phenomena in the basic science literature. There is an urgent need to address these negative consequences of opioid use, in order to maximize the therapeutic benefit that opioids can offer.
- Open Access
- 5 April 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-8
Association between harm reduction strategies and healthcare utilization in patients on long-term prescribed opioid therapy presenting to acute healthcare settings: a protocol for a systematic review and meta-analysis
Opioids are routinely used to treat a variety of chronic conditions associated with pain. However, they are a class of medications with a significant potential for adverse health effects, with and without misuse. Opioid misuse, as defined as inappropriate use of appropriately prescribed opioids, is becoming more well-recognized publicly but does not have clear treatment options. Opioid misuse has been linked to variety of poor outcomes and its consequences have a significant impact on healthcare resource utilization. The evidence on harm reduction strategies to mitigate adverse events prompting presentation to acute care settings for patients presenting with long-term opioid use is sparse. We will perform a systematic review and meta-analysis to catalog effective harm reduction strategies and identify the most effective ones to reduce avoidable healthcare utilization in patients on long-term opioid therapy who present to acute health care settings with complications attributed to opioid misuse. A search strategy will be developed and executed by an information specialist; electronic databases (MEDLINE, EMBASE, CINAHL, Cochrane Library) and additional sources will be searched. Search themes will include opioids, chronic drug use, and acute healthcare settings. Citation screening, selection, quality assessment, and data abstraction will be performed in duplicate. A comprehensive inventory of harm reduction strategies will be developed. Data will be collected on patient-related outcomes associated with each identified harm reduction strategy. When sufficiently homogeneous data on interventions, population, and outcomes is available, it will be pooled for aggregate analysis. Evaluation of the methodological quality of individual studies and of the quality of the body of evidence will be performed. Our primary objective will be to identify harm reduction strategies that have been shown to result in clinically relevant and statistically significant improvements in patient outcomes and/or decreased healthcare utilization. This study will better characterize harm reduction strategies for patients on long-term prescribed opioids presenting to acute healthcare settings. It will also add new knowledge and generate greater understanding of key knowledge gaps of the long-term prescribed opioid use and its impact on healthcare utilization. CRD42018088962 .
- 5 April 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-8
Open AccessAssociation between harm reduction strategies and healthcare utilization in patients on long-term prescribed opioid therapy presenting to acute healthcare settings: a protocol for a systematic review and meta-analysis
Opioids are routinely used to treat a variety of chronic conditions associated with pain. However, they are a class of medications with a significant potential for adverse health effects, with and without misuse. Opioid misuse, as defined as inappropriate use of appropriately prescribed opioids, is becoming more well-recognized publicly but does not have clear treatment options. Opioid misuse has been linked to variety of poor outcomes and its consequences have a significant impact on healthcare resource utilization. The evidence on harm reduction strategies to mitigate adverse events prompting presentation to acute care settings for patients presenting with long-term opioid use is sparse. We will perform a systematic review and meta-analysis to catalog effective harm reduction strategies and identify the most effective ones to reduce avoidable healthcare utilization in patients on long-term opioid therapy who present to acute health care settings with complications attributed to opioid misuse. A search strategy will be developed and executed by an information specialist; electronic databases (MEDLINE, EMBASE, CINAHL, Cochrane Library) and additional sources will be searched. Search themes will include opioids, chronic drug use, and acute healthcare settings. Citation screening, selection, quality assessment, and data abstraction will be performed in duplicate. A comprehensive inventory of harm reduction strategies will be developed. Data will be collected on patient-related outcomes associated with each identified harm reduction strategy. When sufficiently homogeneous data on interventions, population, and outcomes is available, it will be pooled for aggregate analysis. Evaluation of the methodological quality of individual studies and of the quality of the body of evidence will be performed. Our primary objective will be to identify harm reduction strategies that have been shown to result in clinically relevant and statistically significant improvements in patient outcomes and/or decreased healthcare utilization. This study will better characterize harm reduction strategies for patients on long-term prescribed opioids presenting to acute healthcare settings. It will also add new knowledge and generate greater understanding of key knowledge gaps of the long-term prescribed opioid use and its impact on healthcare utilization. CRD42018088962 .
- Open Access
- 12 October 2009
- Published by African Journals Online (AJOL) in East African Medical Journal
- Vol. 77 (9) , 504-7
Use of a simple pain model to evaluate analgesic activity of ibuprofen versus paracetamol
Objective: To evaluate the analgesic activity of ibuprofen against paracetamol using a simple pain model. Design: A double-blind study. Setting: Twenty general practitioners in Harare, Zimbabwe. Patients: Adults with acute sore throat of a maximum of two days’ duration. Interventions: One hundred and thirteen patients with acute pain associated with tonsillopharyngitis randomly received either 400mg ibuprofen or 1000mg paracetamol. The study design included repeated administration up to 48 hours to assess tolerability. Main outcome measures: At hourly intervals for six hours after the first dose of treatment, the patients evaluated pain intensity on swallowing, difficulty in swallowing and global pain relief according to visual analogue scales. Results: Ibuprofen 400mg was significantly more effective than paracetamol 1000mg in all three ratings, at all time-points for pain intensity and difficulty in swallowing, and from two hours onwards for pain relief. There were no serious adverse effects and no statistically significant difference in the incidence of adverse effects in the two treatment groups. Conclusions: Sore throat pain provided a sensitive model to assess the analgesic efficacy of class I analgesics and discriminated between the analgesic efficacy of ibuprofen and paracetamol.
- 12 October 2009
- Published by African Journals Online (AJOL) in East African Medical Journal
- Vol. 77 (9) , 504-7
Open AccessUse of a simple pain model to evaluate analgesic activity of ibuprofen versus paracetamol
Objective: To evaluate the analgesic activity of ibuprofen against paracetamol using a simple pain model. Design: A double-blind study. Setting: Twenty general practitioners in Harare, Zimbabwe. Patients: Adults with acute sore throat of a maximum of two days’ duration. Interventions: One hundred and thirteen patients with acute pain associated with tonsillopharyngitis randomly received either 400mg ibuprofen or 1000mg paracetamol. The study design included repeated administration up to 48 hours to assess tolerability. Main outcome measures: At hourly intervals for six hours after the first dose of treatment, the patients evaluated pain intensity on swallowing, difficulty in swallowing and global pain relief according to visual analogue scales. Results: Ibuprofen 400mg was significantly more effective than paracetamol 1000mg in all three ratings, at all time-points for pain intensity and difficulty in swallowing, and from two hours onwards for pain relief. There were no serious adverse effects and no statistically significant difference in the incidence of adverse effects in the two treatment groups. Conclusions: Sore throat pain provided a sensitive model to assess the analgesic efficacy of class I analgesics and discriminated between the analgesic efficacy of ibuprofen and paracetamol.